- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01648192
Phase I Study of GW856553 (Losmapimod)
July 24, 2017 updated by: GlaxoSmithKline
A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Losmapimod in Healthy Japanese Subjects.
This study is the first study of losmapimod in Japanese subjects.
This study will be a single-center, single blind, phase I and two part study to characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profiles in healthy Japanese volunteers (male and female of non-childbearing potential).
Part1 will be a single dose, randomized, three-period, placebo-controlled and dose escalation part.
Each subject will participate in 3 dosing sessions, and receive, on separate days, three of four treatments of losmapimod 2.5, 7.5 and 20 mg, and the matching placebo in the fasted state after overnight fast (at least 10 hours).
The design incorporates sufficient washout between treatments (at least 7 days after the previous administration), and is an efficient design for the study objectives.
Part 2 will be a fixed dose and placebo-controlled part.
Each subject will participate in one dosing session, and receive losmapimod 7.5 mg or the matching placebo twice daily in the fasted state for 14 days.
Only subjects will be blind to the sequence and dose studied.
The study will include the placebo treatment to allow a valid evaluation of adverse events attributable to treatment versus those independent of treatment.
Approximately 18 subjects in each part will receive treatments of losmapimod and/or placebo in the design.
The primary objective of the study is to characterize the safety and tolerability of single doses and repeat doses of losmapimod in healthy Japanese subjects.
Serial pharmacokinetic samples will be collected and safety assessments will be performed following each dose.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Male or female between 20 and 55 years of age inclusive, at the time of signing the informed consent.
- A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females.
- Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods. This criterion must be followed from the time of the first dose of study medication until follow-up visit.
- Body weight >= 45 kg and BMI within the range 18.5 - 29.0 kg/m2 (inclusive).
- Japanese defined as being born in Japan, having four ethnic Japanese grandparents, holding a Japanese passport or identity papers and being able to speak Japanese. Japanese subjects must not have lived outside of Japan for more than 10 years.
- ALT, alkaline phosphatase and bilirubin <= 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Single QTc, QTcB or QTcF < 450 msec.
Exclusion Criteria:
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen.
- A positive test for HIV antibody.
- History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of greater than 21 units for men and 14 for women or an average daily intake of greater than 3 units. One unit is equivalent to a 285 mL glass of full strength beer or 425 mL schooner of light beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine (NHMRC Guidelines [NHMRC, 2009])
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Pregnant females as determined by positive urine hCG test at screening or prior to dosing.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- History or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Film coated white tablet
|
Experimental: 2.5 mg
Losmapimod for single dose
|
Film coated white tablet
|
Experimental: 7.5 mg
Losmapimod for single dose
|
Film coated white tablet
|
Experimental: 20 mg
Losmapimod for single dose
|
Film coated white tablet
|
Experimental: 7.5 mg BID
Losmapimod for repeat dose (14 days)
|
Film coated white tablet
|
Placebo Comparator: Placebo BID
Placebo
|
Film coated white tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Number of participants with adverse events as a measure of safety and tolerability (evaluated by the result of Clinical safety laboratory tests, vital signs and 12-lead ECG).
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
AUC(0-t)
Time Frame: up to 96h post dose.
|
Area under the concentration-time curve from pre-dose to last time of quantifiable concentration of losmapimod and GSK198602 (inactive metabolite) (Single dose only).
|
up to 96h post dose.
|
AUC(0-inf)
Time Frame: up to 96h post dose.
|
Area under the concentration-time curve from time pre-dose extrapolated to infinite time of losmapimod and GSK198602 (Single dose only).
|
up to 96h post dose.
|
AUC(0-tau)
Time Frame: up to 17 days post dose.
|
Area under the concentration-time curve over the dosing interval of losmapimod and GSK198602 (Repeat dose only).
|
up to 17 days post dose.
|
Cmax
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Maximum observed concentration of losmapimod and GSK198602.
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
tmax
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Time of occurrence of Cmax of losmapimod and GSK198602.
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
t1/2
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Terminal phase half-life of losmapimod and GSK198602
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
accumulation ratios
Time Frame: up to 17 days post dose.
|
accumulation ratios of losmapimod and GSK198602 (Repeat dose only).
|
up to 17 days post dose.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hsCRP
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Change from baseline in hsCRP after the oral dose of losmapimod.
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
phosphorylated HSP27
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Change from baseline in phosphorylated HSP27 assayed following ex vivo stimulation of cells in wholeblood.
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
%AUCex
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Percentage of AUC(0-inf) obtained by extrapolation of losmapimod and GSK198602.
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
tlast
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Time of last quantifiable concentration of losmapimod and GSK198602.
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
λz
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Terminal phase rate constant of losmapimod and GSK198602.
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
CL/F
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Apparent clearance following oral dosing of losmapimod.
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Vz/F
Time Frame: Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
Apparent volume of distribution following oral dosing of losmapimod.
|
Single dose: up to 96h post dose. Repeat dose: up to 17 days post dose.
|
AUC(0-inf)
Time Frame: up to 17 days post dose.
|
Area under the concentration-time curve from time pre-dose extrapolated to infinite time of losmapimod and GSK198602 (Repeat dose only).
|
up to 17 days post dose.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 24, 2012
Primary Completion (Actual)
October 26, 2012
Study Completion (Actual)
October 26, 2012
Study Registration Dates
First Submitted
July 12, 2012
First Submitted That Met QC Criteria
July 19, 2012
First Posted (Estimate)
July 24, 2012
Study Record Updates
Last Update Posted (Actual)
July 26, 2017
Last Update Submitted That Met QC Criteria
July 24, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 116681
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Informed Consent Form
Information identifier: 116681Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 116681Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 116681Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 116681Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 116681Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 116681Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 116681Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
Clinical Trials on Losmapimod for single dose
-
AblynxCompletedHealthy VolunteersUnited States
-
Taiho Pharmaceutical Co., Ltd.CompletedStress Urinary IncontinenceJapan
-
PfizerCompleted
-
Galapagos NVCompleted
-
Bridge Biotherapeutics, Inc.KCRN Research, LLCCompletedHealthy ParticipantsUnited States
-
Longbio PharmaRecruitingParoxysmal Nocturnal Hemoglobinuria (PNH)China
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China
-
Fluart Innovative Vaccine Ltd, HungaryCompleted
-
Longbio PharmaActive, not recruitingChronic Spontaneous UrticariaChina